OBI Pharma (4174) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 浩鼎

OBI Pharma (4174) reported revenue of NT$2.3 million for Oct 2026, -58.7% year on year and +40.8% from the previous month. Revenue for Jan–Oct 2026 was NT$29.6 million (-31.5% year on year).

In Oct 2026, it ranked No. 140 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$1.8 million24/10Nov 2024 NT$2 millionDec 2024 NT$7.8 millionJan 2025 NT$555,000Feb 2025 NT$11 million25/02Mar 2025 NT$2.9 millionApr 2025 NT$5.1 millionMay 2025 NT$3.7 millionJun 2025 NT$3.9 million25/06Jul 2025 NT$4.1 millionAug 2025 NT$1.1 millionSep 2025 NT$5.4 millionOct 2025 NT$5.5 million25/10Nov 2025 NT$7.9 millionDec 2025 NT$7.4 millionJan 2026 NT$1.3 millionFeb 2026 NT$1.6 million26/02Mar 2026 NT$2.6 millionApr 2026 NT$3.4 millionMay 2026 NT$1.5 millionJun 2026 NT$10.3 million26/06Jul 2026 NT$4.1 millionAug 2026 NT$817,000Sep 2026 NT$1.6 millionOct 2026 NT$2.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$2.3 million-58.7%+40.8%
Sep 2026NT$1.6 million-69.7%+98.5%
Aug 2026NT$817,000-23.4%-80.0%
Jul 2026NT$4.1 million-0.6%-60.4%
Jun 2026NT$10.3 million+165.9%+580.5%
May 2026NT$1.5 million-59.5%-56.0%
Apr 2026NT$3.4 million-32.8%+30.7%
Mar 2026NT$2.6 million-9.8%+65.6%
Feb 2026NT$1.6 million-85.5%+19.5%
Jan 2026NT$1.3 million+140.2%-81.9%
Dec 2025NT$7.4 million-5.9%-7.0%
Nov 2025NT$7.9 million+306.2%+43.7%
Oct 2025NT$5.5 million+215.0%+3.2%
Sep 2025NT$5.4 million+14.8%+401.4%
Aug 2025NT$1.1 million-82.1%-74.0%
Jul 2025NT$4.1 million-66.8%+5.8%
Jun 2025NT$3.9 million-51.8%+3.5%
May 2025NT$3.7 million-43.9%-27.0%
Apr 2025NT$5.1 million+19.9%+75.5%
Mar 2025NT$2.9 million-9.4%-73.4%
Feb 2025NT$11 million+145.2%+1,878.2%
Jan 2025NT$555,000-61.2%-92.9%
Dec 2024NT$7.8 million+10.2%+301.5%
Nov 2024NT$2 million-70.1%+11.4%
Oct 2024NT$1.8 million-63.2%-62.4%

Jan–Oct 2026 cumulative: NT$29.6 million (-31.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: OBI Pharma vs PEC / OBI Pharma vs Lotus Pharm / OBI Pharma vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

潤雅子公司提供CDMO之服務收入於滿足履約義務時認列,本月及本年累計完成履約義務較去年減少

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16